Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.

Cancer research using organoid technology

Open access
Kretzschmar, Kai · 2021 · Journal of Molecular Medicine

Abstract

Organoid technology has rapidly transformed basic biomedical research and contributed to significant discoveries in the last decade. With the application of protocols to generate organoids from cancer tissue, organoid technology has opened up new opportunities for cancer research and therapy. Using organoid cultures derived from healthy tissues, different aspects of tumour initiation and progression are widely studied including the role of pathogens or specific cancer genes. Cancer organoid cultures, on the other hand, are applied to generate biobanks, perform drug screens, and study mutational signatures. With the incorporation of cellular components of the tumour microenvironment such as immune cells into the organoid cultures, the technology is now also exploited in the rapidly advancing field of immuno-oncology. In this review, I discuss how organoid technology is currently being utilised in cancer research and what obstacles are still to be overcome for its broader use in anti-cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00109-020-01990-z

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Generation of patient-derived normal and cancer organoids. Patient-derived cancer organoids can be established from primary and metastatic cancer tissue. Matched normal organoids can be generated from normal tissue. Through gene editing, normal organoids may be transformed into cancer organoids. By exposure to genotoxic factors, it may also allow for malignant transformation of normal organoids in vitro, as a recent study showed that normal organoids incubated with genotoxic bacteria acquired mutational signature characteristic of cancer subsets [63]. Some images were modified from the medical art database at https://smart.servier.com/
Fig. 1 Generation of patient-derived normal and cancer organoids. Patient-derived cancer organoids can be established from primary and metastatic cancer tissue. Matched normal organoids can be generated from normal tissue. Through gene editing, normal organoids may be transformed into cancer organoids. By exposure to genotoxic factors, it may also allow for malignant transformation of normal organoids in vitro, as a recent study showed that normal organoids incubated with genotoxic bacteria acquired mutational signature characteristic of cancer subsets [63]. Some images were modified from the medical art database at https://smart.servier.com/CC BY · PubMed Central
Fig. 2 Utilisation of patient-derived organoids in cancer research. Patient-derived (cancer) organoids have already been used to generate ‘living’ organoid biobanks that can be exposed to different drugs for efficacy screenings and drug discovery validations. Organoids have further been used to study inter- and intra-tumour heterogeneity by analysis of mutational signatures, gene expression patterns, or proteomics. By transplanting cancer organoids into mice, tumour cell invasiveness and potential to metastasise can be tested. Finally, approaches to incorporate cells of the tumour microenvironment such as stromal cells (such as cancer-associated fibroblasts) or immune cells (i.e. immuno-oncology) are being developed. Some images were modified from the medical art database at https://smart.servier.com/
Fig. 2 Utilisation of patient-derived organoids in cancer research. Patient-derived (cancer) organoids have already been used to generate ‘living’ organoid biobanks that can be exposed to different drugs for efficacy screenings and drug discovery validations. Organoids have further been used to study inter- and intra-tumour heterogeneity by analysis of mutational signatures, gene expression patterns, or proteomics. By transplanting cancer organoids into mice, tumour cell invasiveness and potential to metastasise can be tested. Finally, approaches to incorporate cells of the tumour microenvironment such as stromal cells (such as cancer-associated fibroblasts) or immune cells (i.e. immuno-oncology) are being developed. Some images were modified from the medical art database at https://smart.servier.com/CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Research works printed but not linked: 1

  1. Betge J et al. (2019), Multiparametric phenotyping of compound effects on patient derived organoids. bioRxiv:660993

Cited by

See all 123

Metadata

Authors
Kretzschmar, K.
Affiliations
Universitätsklinikum Würzburg (DE)
Corresponding author
Kretzschmar, Kai
Venue
Journal of Molecular Medicine
Published
2020-10-14
Volume
99
Issue
4
Pages
501-515
ISSN
  • 0946-2716 (ISSN-L)
  • 1432-1440
OpenAlex
W3093085024
Cited by
120
References
141
Citations by year
2026: 13 · 2025: 29 · 2024: 32 · 2023: 22 · 2022: 14 · 2021: 9 · 2020: 1
FWCI
1.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
Funders
Deutsche Krebshilfe (MSNZ Würzburg)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
tumor organoids, organoid technology, cancer biobank, drug screening, mutational signatures, tumor microenvironment, immune cells, cancer immunotherapy, cancer therapy, cancer genes
MeSH terms
Cell Transformation, Neoplastic, DNA Mutational Analysis, Drug Screening Assays, Antitumor, Epithelial Cells, Forecasting, Humans, Medical Oncology, Neoplasm Metastasis, Neoplasms, Organoids, Neoplastic Stem Cells, Biological Specimen Banks, Genes, Neoplasm, Translational Research, Biomedical, Stem Cell Research, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer research using organoid technology. https://app.cochat.ai/papers/10.1007/s00109-020-01990-z
The paper
Kretzschmar, K. (2021). Cancer research using organoid technology. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-020-01990-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.